Antibiotic resistance in pathogens of community-acquired respiratory tract infections;Antibiotika-resistenz bei erregern ambulant erworbener atemwegsinfektionen

Chemotherapie Journal

Volumn 11, Issue 1, 2002, Pages 12-26

  Ewig, Santiago ^a   Reinert, Ralf René ^a   Wiedemann, Bernd ^a   Mehl, Michael ^a   Rodloff, Arne C ^a   Trautmann, Matthias ^a   Pletz, Mathias W ^a   Lode, Hartmut ^a   Kardos, Peter ^a   Shah, Pramod ^a   Kresken, Michael ^a   Brauers, Johannes ^a  

^a Antiinfectives Intelligence GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; DALFOPRISTIN; ERYTHROMYCIN; FOSFOMYCIN; IMIPENEM; KETOLIDE; LEVOFLOXACIN; MACROLIDE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOMYCIN; TELITHROMYCIN; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HUMAN; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; NONHUMAN; OTITIS MEDIA; RESPIRATORY TRACT INFECTION; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0036176404     PISSN: 09406735     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Prospective study of the incidence, etiology and outcome of adult lower respiratory tract illness in the community
2. Infective exacerbations of chronic bronchitis: Relation between bacteriologic etiology and lung function
3. Antimicrobial resistance and type distribution of Streptococcus pneumoniae in Germany
4. Antibiotic resistance of S. pyogenes and S. pneumoniae strains isolated from infections of outpatients in Germany, 1999-2000
5. Antimicrobial resistance of Streptococcus pneumoniae from outpatients with respiratory tract infections in Germany from 1998 to 1999
6. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens - Findings of the Alexander Project 1992-1996
7. Antipneumococcal activity of telithromycin by agar dilution, microdilution, E test, and disk diffusion methodologies
8. Influence of variations in test methods on susceptibility of Haemophilus influenzae to ampicillin, azithromycin, clarithromycin, and telithromycin
9. Rate of carriage, serotype distribution and penicillin resistance of Streptococcus pneumoniae in healthy children
10. Population biology of Streptococcus pneumoniae isolated from oropharyngeal carriage and invasive disease
11. Prevalence of Haemophilus influenzae pharyngeal carriers in the school population of Catalonia
12. Oropharyngeal colonization in the elderly
13. Oropharyngeal gram-negative bacillary carriage in chronic obstructive pulmonary disease: Relation to severity of disease
14. Nasal colonization by Staphylococcus aureus in active, independent, community seniors
15. Nasal carriage as a source of Staphylococcus aureus bacteriemia
16. Antibiotic resistance rates and macrolide resistance phenotypes of viridans group streptococci from the oropharynx of healthy Greek children
17. Pharmacokinetics and pharmacodynamics of new and old antimicrobial agents for acute otitis media
18. Pharmacokinetic/pharmacodynamic parameters. Rationale for antibacterial dosing of mice and men
19. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections
20. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
21. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection
22. Pharmacodynamics of levofloxacin
23. Pharmacokinetics of sparfloxacin and serum bactericidal activity against pneumococci
24. Clinical pharmacology of the fluoroquinolones: Studies in human dynamic/kinetic models
25. Serum and WBC pharmacokinetics of 1500 mg of azithromycin when given either as a single dose or over a 3 day period in healthy volunteers
26. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy
27. In vitro development of resistance to Telithromycin (HMR 3647), four Macrolides, Clindamycin, and Pristinamycin in Streptococcus pneumoniae
28. In vitro selection of resistance to four β-lactams and azithromycin in Streptococcus pneumoniae
29. Community-acquired pneumonia guidelines - An international comparison: A view from Europe
30. The evolving threat of antibiotic resistance in Europe: New data from the Alexander Project
31. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain
32. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia
33. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence
34. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997
35. Development of resistance during antimicrobial therapy: A review of antibiotic classes and patient characteristics in 173 studies
36. American Thoracic Society Guidelines for the management of adults with community-acquired pneumonia
37. Contemporary use of guidelines in 1089 adults presenting with acute lower respiratory tract illness in general practice in the U.K.: Implications for developing management guidelines
38. The etiology of acute otitis media (AOM) in children
39. Alteration of clinical picture and treatment of pediatric acute otitis media over the past two decades
40. Kurzzeitherapie mit cefuroximaxetil über fünf tage im vergleich zur zehn-tage-therapie mit clarithromycin bei akuter sinusitis
41. Rationale therapie bakterieller atemwegsinfektionen
42. Antimicrobial resistance in Streptococcus pyogenesu isolates in Berlin
43. Telithromycin has excellent activity against respiratory pathogens collected from Germany in the Protekt study
44. Alexander Project 1998: Comparative in vitro activity of 20 antimicrobíals against 8885 community-acquired respíratory tract ísolates
45. Ambulant erworbene atemwegsínfektionen. Aktuelle daten zur wirksamkeít und resístenzsítuatíon verschíedener antibiotikagruppen gegenüber den wichtigsten bakteriellen spezies
46. Resistenzsítuation bei klinísch wíchtigen infektionserregern gegenüber chemotherapeutíka in mitteleuropa, ergebnisse einer multizentríschen studíe der arbeitsgemeinschaft "resistenz" in der Paul-Ehrlich-Gesellschaft für chemotherapie e. V. aus dem Jahre 1998
47. Susceptibility pattern of Streptococcus pneumoniae in outpatients in Germany
48. Increase of erythromycin resistance among clinical isolates of Streptococcus pneumoniae in Germany
49. Antimicrobíal resístance of Streptococcus pneumoniae recovered from respiratory tract infection (RTI) of outpatíents in Germany, 1998-1999: Results of a 20-center national surveíllance study
50. Bacterial resístance to macrolíde, lincosamide and streptogramin antibiotics by target modíficatíon
51. Distribution of genes encoding resistance to macrolídes, líncosamides and streptogramíns among staphylococci
52. Pneumococcal macrolide resistance - Not a myth
53. The levels of clarithromycin and its 14-hydroxy metabolite in the lung
54. Comparative in vitro activity of HMR 3647, azithromycin, clarithromycin and roxithromycin against S. pneumoniae and Staphylococcus aureus
55. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin
56. Impact of macrolide resistance on the in vivo actívity of a new ketolide, HMR 3647, agaínst S. pneumoniae and S. aureus
57. High ín vitro susceptibílíty of the ketolide telithromycin (HMR 3647) in clinical isolates of key respiratory pathogens